A 76-year-old man with non-valvular atrial fibrillation, hypertension and type 2 diabetes presents for routine review. He has normal renal function and has never had a stroke or transient ischaemic attack. According to the 2020 CCS atrial fibrillation guideline, what is the MOST appropriate antithrombotic strategy?